

Mariagrazia Michieli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/623115/publications.pdf>

Version: 2024-02-01

85
papers

2,435
citations

236912
25
h-index

214788
47
g-index

85
all docs

85
docs citations

85
times ranked

2150
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 393-399.	2.4	29
2	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. Hematological Oncology, 2019, 37, 447-455.	1.7	25
3	The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 378-384.	1.4	3
4	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 2019, 54, 1625-1631.	2.4	11
5	Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. Leukemia Research, 2019, 76, 33-38.	0.8	31
6	Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. Bone Marrow Transplantation, 2018, 53, 228-230.	2.4	7
7	â€œTwistin' the night awayâ€ Fertility preservation in young adult female cancer survivors. Cancer, 2017, 123, 707-708.	4.1	0
8	Low-dose radiotherapy in diffuse large B-cell lymphoma. Hematological Oncology, 2017, 35, 472-479.	1.7	9
9	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. Clinical Genitourinary Cancer, 2017, 15, 163-167.	1.9	3
10	Autologous stem cell transplantation in HIV-positive patients affected by relapsed/partially responding lymphoma: let it be. Expert Review of Hematology, 2016, 9, 617-619.	2.2	3
11	Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia, 2016, 30, 1201-1204.	7.2	19
12	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplantation, 2016, 51, 384-390.	2.4	7
13	Cancer survivorship: Is there a role for cancer survivor clinics?. Journal of Clinical Oncology, 2016, 34, e272-e272.	1.6	0
14	The long and winding road in cancer survivorship care. Cancer, 2015, 121, 3748-3749.	4.1	0
15	Postautologous stem cell transplantation long-term outcomes in 26 HIV-positive patients affected by relapsed/refractory lymphoma. Aids, 2015, 29, 2303-2308.	2.2	8
16	Î³-Herpesvirus Load as Surrogate Marker of Early Death in HIV-1 Lymphoma Patients Submitted to High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation. PLoS ONE, 2015, 10, e0116887.	2.5	5
17	Autograft HIV-DNA Load Predicts HIV-1 Peripheral Reservoir After Stem Cell Transplantation for AIDS-Related Lymphoma Patients. AIDS Research and Human Retroviruses, 2015, 31, 150-159.	1.1	6
18	Survivorship Care Plans: A Change of Perspective or a Failure. Journal of Clinical Oncology, 2014, 32, 3904-3905.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Reply to long-term survivorship clinics led by primary care physicians within the cancer center may be a good option for coordinated survivorship care. <i>Cancer</i> , 2014, 120, 3753-3754.	4.1	0
20	Which tools may help physicians in female fertility prediction after autologous bone marrow transplantation for lymphoma? A pilot study. <i>Journal of Chemotherapy</i> , 2014, 26, 293-299.	1.5	6
21	Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. <i>Rheumatology</i> , 2014, 53, 381-382.	1.9	21
22	Cancer survivorship: Is there a role for cancer survivor clinics?. <i>Cancer</i> , 2014, 120, 1908-1909.	4.1	5
23	Long term cryopreservation in 5% DMSO maintains unchanged CD ³⁴ cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation. <i>Vox Sanguinis</i> , 2013, 105, 77-80.	1.5	23
24	Stem cell mobilization in HIV seropositive patients with lymphoma. <i>Haematologica</i> , 2013, 98, 1762-1768.	3.5	27
25	Nutrition in oncologic patients during antineoplastic treatment. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 120.	3.0	2
26	Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antineoplastic Chemotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1438-1443.	1.7	4
27	Autologous Stem Cell Transplantation as a Care Option in Elderly Patients. A Review. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1419-1429.	1.7	6
28	Antineoplastic Treatment, for Solid Tumors, during Pregnancy: A Crucial Decision. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 1-19.	2.1	1
29	Antineoplastic Treatment and Hematological Malignancies during Pregnancy: A Crucial Decision. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 21-32.	2.1	0
30	Obstetrical, Fetal and Postnatal Effects of Gestational Antineoplastic Chemotherapy: How to Counsel Cancer Patients. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 33-46.	2.1	2
31	High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 788-793.	2.0	102
32	Stem Cell Transplantation for Lymphoma Patients with HIV Infection. <i>Cell Transplantation</i> , 2011, 20, 351-370.	2.5	23
33	<i>Mycobacterium tuberculosis</i> : An Infection We Should Suspect in Bone Marrow Transplantation. <i>Journal of Chemotherapy</i> , 2011, 23, 312-313.	1.5	2
34	BU/melphalan and auto-SCT in AML patients in first CR: a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective study. <i>Bone Marrow Transplantation</i> , 2010, 45, 640-646.	2.4	17
35	A new freezing and storage procedure improves safety and viability of hematopoietic stem cells and neutrophil engraftment: a single institution experience. <i>Vox Sanguinis</i> , 2010, 98, 172-180.	1.5	13
36	Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIV-Infected versus HIV-Uninfected Patients with Relapsed or Refractory Lymphoma. <i>Clinical Infectious Diseases</i> , 2010, 50, 1672-1679.	5.8	45

#	ARTICLE	IF	CITATIONS
37	Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. <i>Annals of Oncology</i> , 2010, 21, 1482-1485.	1.2	19
38	Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2192-2198.	1.6	116
39	Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. <i>Human Pathology</i> , 2009, 40, 1045-1049.	2.0	5
40	High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. <i>Blood</i> , 2009, 114, 1306-1313.	1.4	130
41	Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. <i>Blood</i> , 2009, 113, 6011-6014.	1.4	131
42	Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor. <i>Vox Sanguinis</i> , 2008, 94, 342-350.	1.5	5
43	Recent thymic emigrants in lymphoma patients with and without human immunodeficiency virus infection candidates for autologous peripheral stem cell transplantation. <i>Clinical and Experimental Immunology</i> , 2008, 151, 101-109.	2.6	7
44	The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2008, 77, 460-465.	2.5	35
45	Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 35-41.	3.5	216
46	IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. <i>Bone Marrow Transplantation</i> , 2007, 40, 1019-1025.	2.4	20
47	Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. <i>Blood</i> , 2005, 105, 1891-1897.	1.4	195
48	Autologous stem cell transplantation for HIV-infected individuals with relapsed lymphomas: no longer an experimental strategy. <i>Blood</i> , 2005, 105, 439-440.	1.4	9
49	Is high-dose chemotherapy with peripheral stem cell rescue a suitable option for elderly patients affected by aggressive non-Hodgkin's lymphoma?. <i>Annals of Oncology</i> , 2005, 16, 837-838.	1.2	2
50	Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma. <i>Aids</i> , 2004, 18, 1859-1861.	2.2	2
51	Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: Onset versus relapse expression. <i>Cytometry</i> , 2004, 59B, 40-45.	1.8	7
52	Ann Arbor Stage Is the Most Important Predictor of Survival for Refractory and Relapsed HIV-Associated Lymphoma Enrolled in a Program of High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 893-893.	1.4	1
53	Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2003, 71, 1-8.	2.2	27
54	A phase II study of \pm -interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. <i>Leukemia</i> , 2003, 17, 554-559.	7.2	11

#	ARTICLE	IF	CITATIONS
55	Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia. <i>Clinical Pharmacokinetics</i> , 2003, 42, 851-862.	3.5	11
56	High-Dose Therapy and Autologous Peripheral-Blood Stem-Cell Transplantation As Salvage Treatment for HIV-Associated Lymphoma in Patients Receiving Highly Active Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 4423-4427.	1.6	144
57	CD34+-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection. <i>Annals of Oncology</i> , 2003, 14, 475-480.	1.2	22
58	Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. <i>Blood</i> , 2003, 102, 3043-3051.	1.4	52
59	Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. <i>Annals of Hematology</i> , 2002, 81, 462-466.	1.8	28
60	P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in <i>de novo</i> adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 116, 519-527.	2.5	34
61	Dendritic cell recovery after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 261-266.	2.4	23
62	CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. <i>Haematologica</i> , 2002, 87, 1135-40.	3.5	34
63	Amifostine Does Not Inhibit the Toxic Effects of Anthracycline Derivates or Mitoxantrone on MDR Tumor Cell Lines. <i>Leukemia and Lymphoma</i> , 2001, 42, 721-729.	1.3	2
64	Fludarabine, Arabinosyl Cytosine and Idarubicin (FLAI) for Remission Induction in Poor-Risk Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 40, 335-343.	1.3	25
65	P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2000, 108, 703-709.	2.5	42
66	Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 279-286.	2.3	26
67	P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in <i>de novo</i> acute non-lymphocytic leukaemias: biological and clinical implications. <i>British Journal of Haematology</i> , 1999, 104, 328-335.	2.5	103
68	Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. <i>British Journal of Haematology</i> , 1999, 106, 92-99.	2.5	48
69	FLOW CYTOMETRY EVALUATION OF PLASMA CELLS CONTAMINATING LEUKAPHERESIS PRE- AND POST-CD34-POSITIVE SELECTION. <i>British Journal of Haematology</i> , 1999, 105, 567-567.	2.5	3
70	Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. <i>European Journal of Clinical Pharmacology</i> , 1999, 55, 361-368.	1.9	25
71	Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery. <i>Bone Marrow Transplantation</i> , 1999, 24, 757-761.	2.4	3
72	Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. <i>Leukemia</i> , 1998, 12, 1236-1240.	7.2	20

#	ARTICLE	IF	CITATIONS
73	P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. British Journal of Haematology, 1997, 96, 356-365.	2.5	68
74	Screening for Multidrug Resistance in Leukemia: Cell Reactivity to MRK-16 Correlates with Anthracycline Retention and Sensitivity of Leukemic Cells. Leukemia and Lymphoma, 1996, 23, 99-105.	1.3	4
75	The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells, 1995, 13, 428-434.	3.2	29
76	P170 Glycoprotein Expression and Impaired Anthracycline Retention in Chronic Myeloid Leukaemia. Leukemia and Lymphoma, 1995, 17, 289-294.	1.3	8
77	Evaluation of the Clinical Relevance of the Anionic Glutathione-S-Transferase (GST) and Multidrug Resistance (mdr-1) Gene Coexpression in Leukemias and Lymphomas. Leukemia and Lymphoma, 1994, 15, 453-468.	1.3	15
78	A Comparative Analysis of the Sensitivity of Multidrug Resistant (MDR) and Non-MDR Cells to Different Anthracycline Derivatives. Leukemia and Lymphoma, 1993, 9, 255-264.	1.3	40
79	D-Verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin. Anti-Cancer Drugs, 1993, 4, 173-180.	1.4	11
80	Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. European Journal of Haematology, 1992, 48, 87-92.	2.2	54
81	Immunohistochemical detection of the multidrug transport protein P1 70 in human normal tissues and malignant lymphomas. Histopathology, 1991, 19, 131-140.	2.9	94
82	mdr-1 GENE AMPLIFICATION IN ACUTE LYMPHOBLASTIC LEUKAEMIA PRIOR TO ANTILEUKAEMIC TREATMENT. British Journal of Haematology, 1991, 78, 288-289.	2.5	17
83	Comparison of the DNA Content, Bromodeoxyuridine Incorporation and Ki-67 Antigen Expression in Human Acute Myeloid Leukemia. Leukemia and Lymphoma, 1990, 3, 45-51.	1.3	10
84	Treatment of Ph+ chronic myeloid leukemia by gamma interferon. Blut, 1989, 59, 15-20.	1.2	9
85	Treatment of hairy-cell leukaemia with $\hat{1}\pm$ -interferon ($\hat{1}\pm$ -IFN). European Journal of Cancer & Clinical Oncology, 1988, 24, 195-200.	0.7	24